Therapy of 125 I particles implantation inhibited the local growth of advanced non-small cell lung cancer: a retrospective clinical study.

Autor:	Dai F; Department of Interventional Oncology, Gansu Provincial Hospital Lanzhou, Gansu, China., Wang J; Department of Interventional Oncology, Gansu Provincial Hospital Lanzhou, Gansu, China., An H; Department of Interventional Therapy, Tianzhu County People's Hospital Tianzhu, Gansu, China., Lei T; Department of Reproductive Center, Minle County Maternity and Child-Care Hospital Minle, Gansu, China., Tang K; Department of Medical Imaging, Linxia State Hospital Linxia, Gansu, China., Ma X; Department of Radiotherapy, Gansu Provincial Hospital Lanzhou, Gansu, China., Duo P; Second Department of Surgery, Minle County Chinese Medicine Hospital Minle, Gansu, China., Ren P; Department of Interventional Therapy, Minle County Chinese Medicine Hospital Minle, Gansu, China., Chai W; Department of Interventional Oncology, Gansu Provincial Hospital Lanzhou, Gansu, China.
Jazyk:	angličtina
Zdroj:	American journal of translational research [Am J Transl Res] 2019 Jun 15; Vol. 11 (6), pp. 3737-3749. Date of Electronic Publication: 2019 Jun 15 (Print Publication: 2019).
Abstrakt:	Background: The aim of this study was to investigate the efficacy and safety of 125 I particle implantation for treating advanced non-small cell lung cancer (NSCLC). Methods: Data from 56 patients with advanced NSCLC between January 2013 and May 2016 were retrospectively analyzed. The changes of tumor size, objective response rate (ORR), disease control rate (DCR), survival rate of patients and occurrence rate of complications were calculated, and the levels of carcinoembryonic antigen (CEA) and cytokerantin-19-fragment (CYFRA21-1) before and after the treatment were evaluated. Results: The 125 I particles implantation therapy significantly inhibited the tumor local growth of NSCLC (from 7.75±6.69 to 3.39±2.12 cm) (P<0.001), suggesting a better effectiveness with an RR of 55.4% and DCR of 98.2%. In addition, the 125 I particle implantation down-regulated the CEA expression level of lung adenocarcinoma (LAC) patients (P<0.05). The one-year, two-year, three-year survival rate were 41.1%, 39.3% and 19.6% respectively after the implantation therapy. However, patients implanted 125 I particles had no serious complications except for slight fever. Conclusions: NSCLC patients at different clinical features all can benefit from the 125 I particle implantation therapy. Moreover, the level of CEA can be used as an efficacy predictor for the 125 I particle implantation therapy for LAC. Competing Interests: None.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu